NBP vs NCEL

NovaBridge Biosciences vs NewcelX Ltd. — Valuation Comparison 2026

NBP

Pharmaceutical Preparations
NovaBridge Biosciences
Quality
3.0
out of 10
Value Trap
12
SAFE
Price
$1.84
Last close
Models
9/13
Active
VS

NCEL

Pharmaceutical Preparations
NewcelX Ltd.
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$3.52
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NBP Fair ValueNBP Upside NCEL Fair ValueNCEL Upside
Bayesian DCF Intrinsic $0.34 -81.4% $0.86 -75.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.15 +16.8% $2.43 -30.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NBP vs NCEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NBP vs NCEL — Which Stock Is More Undervalued?

NBP scores higher with a 3.0/10 quality rating vs NCEL's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NovaBridge Biosciences (NBP) and NewcelX Ltd. (NCEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NBP currently trades at $1.84 with a QOC of 3.0/10, while NCEL trades at $3.52 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).